Genomic Valley Biotech Ltd Stock Price Today (NSE: GVBL)

Genomic Valley Biotech Ltd

31.00+0.01 (+0.03%)
Market Closed

Fundamental Score

...

Genomic Valley Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Genomic Valley Biotech Ltd share price today is 31.00, up +0.03% on NSE/BSE as of 17 June 2026. Genomic Valley Biotech Ltd (GVBL) is a Small-cap company in the Biotechnology sector with a market capitalisation of 8.81 (Cr). The 52-week high for GVBL share price is 54.27 and the 52-week low is 20.10. At a P/E ratio of 88.14x, GVBL is currently trading above its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 9.68% and a debt-to-equity ratio of 0.00.

Genomic Valley Biotech Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
31.00
Low
22.05
Volume
854.0526315789474
Change
+5.07%

Genomic Valley Biotech Ltd share price chart: 5.07% return over the past month. 52-week high ₹54.27, 52-week low ₹20.10.

Genomic Valley Biotech Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
26.5426.5426.5426.5450.00 (Cr)
26.5426.5426.5426.541.00 (Cr)
26.5426.5426.5426.54240.00 (Cr)
26.5426.5426.5426.540.00 (Cr)
26.5426.5426.5426.540.00 (Cr)
26.5426.5426.5426.540.00 (Cr)
26.5426.5426.5426.5430.00 (Cr)
26.6726.6726.6726.673.54K (Cr)
23.1725.4023.1725.4071.00 (Cr)
24.2324.2524.2324.2561.00 (Cr)

Genomic Valley Biotech Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
26.5426.5426.5426.54+0.00%
24.5026.6722.0526.54+8.33%
26.7529.9523.0424.25-9.35%
28.5029.9420.5828.00-1.75%
21.4129.5020.2028.50+33.12%
25.4929.9020.1025.90+1.61%
30.0030.3521.0124.71-17.63%
30.1038.2027.1530.66+1.86%
32.3534.0027.1530.40-6.03%
41.7044.5032.3132.52-22.01%
47.2153.4937.8941.74-11.59%
50.4753.1846.4649.68-1.57%

AI Research Briefing

Powered by Gemini · 2026-04-10

Micro-cap horticulture firm trading at biotech valuations; a correction is inevitable.

Research Confidence
8.0/10High
MICRO-CAP DARK HORSEBreakdown: 1M: -5.13%, 3M: -30.96%, 6M: -37.64%Expensive: P/E 88.14x vs Industry P/E 51.82x. Negative P/E ratio of -174.3.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. Genomic Valley Biotech's promoters confirmed no encumbrance of shares throughout FY26.

CORE STORY (THE REAL GAME)

This is *not* a biotech innovation play. GVBL is a micro-cap engaged in low-tech horticulture and trading of agricultural products. The market is likely misclassifying it within the broader 'biotech' hype, hoping for a high-growth re-rating.

Why Now
  • Sectoral tailwinds in Indian biotech
  • Low free float leads to volatility
  • No encumbrance of promoter shares
Potential Catalysts
  • Significant order win in core horticulture business
  • Acquisition by a larger agricultural company
  • Positive change in YoY profit growth
Key Risks
  • Micro-cap with extreme illiquidity
  • Revenue declined 77.27% YoY in the latest quarter
  • Overvalued: P/E 88.14x vs Industry P/E 51.82x
Institutional Activity

Promoter holding steady at 46.72%. No change in FII/DII activity.

Macro Context

Indian biotech sector projected to reach $300 billion by 2030, but GVBL's focus is on low-tech horticulture.

Cash Flow Quality

Profit not converting to cash. Free Cash Flow 5Y: ₹3.82 Cr

3–6 Month Outlook

Expect a correction as the market realizes GVBL's limited growth potential in low-tech horticulture. Downside risk is significant.

Primary Thesis Risk

Misclassification as a biotech play leads to valuation bubble; revenue collapse will trigger a sharp correction.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

9.68%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

11.83%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

20.70%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Genomic Valley Biotech Ltd Valuation Check

Poor

Price to Earnings (P/E)

88.14x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

51.82x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

46.72%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-100.00%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-57.14%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-0.24%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

4.42%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

4.42%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

3.82 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Genomic Valley Biotech Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GVBL across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Strong Operating Margins (20.70%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (9.68%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Premium Valuation Risk (P/E: 88.14x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-100.00%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-57.14%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-0.24% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (4.42% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (4.42% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Genomic Valley Biotech Ltd vs Biotechnology Peers

Peer Comparison - Biotechnology

Compare Genomic Valley Biotech Ltd with 4 other companies in the same sector

5 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
24.6/100
31
₹8.81
88.1
Average
9.68%
Poor
11.83%
Average
0.0
Excellent
4.42%
Average
-0.24%
Poor
0.00%
63.7/100
757
₹37009.24
79.9
Average
20.83%
Excellent
28.50%
Excellent
0.0
Excellent
37.27%
Excellent
23.86%
Excellent
0.00%
63.6/100
372
₹3493.23
23.7
Average
9.54%
Poor
13.11%
Average
0.0
Excellent
0.26%
Average
7.48%
Good
1.66%
25/100
117
₹177.38
51.62%
Excellent
51.62%
Excellent
0.0
Excellent
105.89%
Excellent
0.00%
16/100
27
₹68.05
16.6
Average
5.68%
Poor
9.04%
Poor
0.6
Good
-3.27%
Poor
-3.35%
Poor
0.00%

Genomic Valley Biotech Ltd PE Ratio History

Historical price-to-earnings ratio for GVBL — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20251.17₹24.7121.1x
FY 20240.05₹79.951599x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Genomic Valley Biotech Ltd Quarterly Performance

Latest quarterly metrics for GVBL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-57.14%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-100.00%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-0.24%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

4.42%

Compounded annual net profit growth over 5 years

Genomic Valley Biotech Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GVBL — calculated from daily price history

61RSI 14
Neutral — RSI 61

Momentum is balanced — neither overbought nor oversold.

SMA 50
26
▲ Price above SMA 50 — Short-term bullish
SMA 200
31
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Genomic Valley Biotech Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Genomic Valley Biotech Ltd (GVBL) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Genomic Valley Biotech Ltd

About GVBL (Genomic Valley Biotech Ltd)

Genomic Valley Biotech Ltd is a pioneering force in the Indian biotechnology landscape, specializing in the meticulous cultivation and enhancement of agricultural resources. Throug...h innovative approaches, GVBL focuses on leveraging cutting-edge genomic techniques to improve crop yields, enhance nutritional value, and bolster resilience against environmental stressors. The company's research and development initiatives are dedicated to the identification and propagation of superior plant varieties, employing advanced breeding methodologies and genetic engineering to develop crops with enhanced traits, such as disease resistance, pest tolerance, and improved shelf life. GVBL operates state-of-the-art laboratories and cultivation facilities, where scientists and agricultural experts collaborate to translate groundbreaking research into tangible solutions for the agricultural sector. GVBL's commitment to sustainable agricultural practices is reflected in its emphasis on environmentally friendly cultivation methods. The company actively promotes the use of bio-fertilizers, biopesticides, and water conservation technologies to minimize the environmental impact of its operations. Through precision agriculture techniques and data-driven analysis, GVBL optimizes resource utilization and minimizes waste, ensuring both economic efficiency and ecological responsibility. The company also engages in collaborative projects with farmers and agricultural communities, providing training and support to promote the adoption of sustainable farming practices. By integrating scientific innovation with environmental stewardship, GVBL aims to contribute to a more resilient and sustainable agricultural ecosystem. Beyond its core focus on crop improvement, GVBL is actively involved in developing novel biotechnological solutions for various agricultural challenges. The company's research portfolio includes the development of diagnostic tools for plant diseases, the creation of biostimulants to enhance plant growth, and the exploration of microbial solutions for soil health management. GVBL is dedicated to addressing the evolving needs of the agricultural sector, collaborating with industry partners, research institutions, and government agencies to accelerate the development and deployment of innovative biotechnological solutions. By fostering collaboration and embracing cutting-edge technologies, GVBL is poised to drive advancements in agricultural productivity and contribute to food security in India and beyond.

Company Details

Symbol:GVBL
Industry:Biotechnology
Sector:Biotechnology

Key Leadership

Mr. Yogesh Agrawal
MD, Chairman & CFO
Ms. Anupam Aditya
Company Secretary & Compliance Officer

GVBL Share Price: Frequently Asked Questions

What is the current share price of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd (GVBL) trades at ₹31.00 on NSE and BSE. Market cap ₹8.81 (Cr). Educational data only.

What is the P/E ratio of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has a P/E of 88.14x vs industry average 51.82x.

What is the Bull Run score for Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has a Bull Run score of 24.6/100 based on 25+ financial parameters.

Does Genomic Valley Biotech Ltd pay dividends?

Genomic Valley Biotech Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has ROE of 9.68%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has debt-to-equity of 0.00.

Is Genomic Valley Biotech Ltd a good investment?

Bull Run gives Genomic Valley Biotech Ltd a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.